Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dengue virus nonstructural protein 1 (NS1) is a 46–55 kDa glycoprotein that is essential for viral replication and is a key mediator of dengue pathogenesis (Muller et al., 2013, Antiviral Res). It exists in three distinct oligomeric states: an intracellular monomer, a membrane-associated dimer involved in the viral replication complex, and a secreted hexamer (sNS1) that circulates in the blood of infected patients (Gutsche et al., 2011, PNAS). The secreted hexamer acts as a potent virulence factor by directly inducing vascular endothelial cell permeability and triggering the release of pro-inflammatory cytokines, which can lead to life-threatening conditions like Dengue Hemorrhagic Fever (DHF) and Dengue Shock Syndrome (DSS) (Beatty et al., 2015, Sci Transl Med). NS1 also facilitates immune evasion by interacting with and inhibiting components of the complement system, such as C4 and factor H (Avirutnan et al., 2010, PLoS Pathog). Due to its high concentration in patient serum during the early stages of infection, NS1 is widely used as a diagnostic biomarker (Amorim et al., 2014, Rev Soc Bras Med Trop). Therapeutic efforts focus on developing monoclonal antibodies, such as 2B7 and VIS513, which target specific epitopes on the NS1 protein to neutralize its toxic effects and prevent vascular leakage (Wan et al., 2017, Nat Commun; He et al., 2017, J Virol). However, a significant challenge in targeting NS1 epitopes is the risk of molecular mimicry, where anti-NS1 antibodies may cross-react with host proteins like fibrinogen or platelets, potentially exacerbating bleeding or causing autoimmune issues (Cheng et al., 2009, J Clin Invest).
Neutralization of secreted NS1 (sNS1) to prevent vascular leakage and inhibition of NS1-mediated immune evasion.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dengue virus nonstructural protein 1 (NS1) (NS1).